Atara Biotherapeutics, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Pascal Touchon. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Pascal Touchon has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ATRA / Atara Biotherapeutics, Inc. Director 77,955
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Pascal Touchon. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ATRA / Atara Biotherapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ATRA / Atara Biotherapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ATRA / Atara Biotherapeutics, Inc. Insider Trades
Insider Sales ATRA / Atara Biotherapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ATRA / Atara Biotherapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-08-16 ATRA Touchon Pascal 2,762 6.6290 2,762 6.6290 18,309 237 5.3000 -3,670 -20.05
2024-08-16 ATRA Touchon Pascal 276 6.6300 276 6.6300 1,830
2024-05-16 ATRA Touchon Pascal 81,506 0.6170 3,260 15.4250 50,289
2024-03-04 ATRA Touchon Pascal 24,844 0.7200 994 18.0000 17,888
2023-11-16 ATRA Touchon Pascal 20,409 0.3890 816 9.7250 7,939
2023-08-16 ATRA Touchon Pascal 21,432 1.6520 857 41.3000 35,406
2023-08-16 ATRA Touchon Pascal 9,334 1.6530 373 41.3250 15,429
2023-06-27 ATRA Touchon Pascal 14,291 1.6600 572 41.5000 23,723
2023-05-16 ATRA Touchon Pascal 29,766 2.0370 1,191 50.9250 60,633

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ATRA / Atara Biotherapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Pascal Touchon as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-12 2025-06-10 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 7,828 77,955 11.16
2024-08-20 2024-08-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -276 70,127 -0.39 6.63 -1,830 464,942
2024-08-20 2024-08-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -2,762 70,403 -3.78 6.63 -18,309 466,701
2024-05-20 2024-05-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -81,506 1,829,146 -4.27 0.62 -50,289 1,128,583
2024-03-06 2024-03-04 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -24,844 1,910,652 -1.28 0.72 -17,888 1,375,669
2024-01-09 2024-01-08 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 1,280,000 1,935,496 195.27
2023-11-20 2023-11-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -20,409 655,496 -3.02 0.39 -7,939 254,988
2023-08-18 2023-08-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -9,334 675,905 -1.36 1.65 -15,429 1,117,271
2023-08-18 2023-08-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -21,432 685,239 -3.03 1.65 -35,406 1,132,015
2023-06-29 2023-06-27 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -14,291 706,671 -1.98 1.66 -23,723 1,173,074
2023-05-18 2023-05-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale -29,766 720,962 -3.96 2.04 -60,633 1,468,600
2023-03-06 2023-03-02 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -15,679 750,728 -2.05 3.63 -56,868 2,722,890
2023-03-03 2023-03-01 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 324,711 766,407 73.51
2022-11-18 2022-11-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -15,591 441,696 -3.41 4.49 -70,004 1,983,215
2022-08-18 2022-08-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -14,806 457,287 -3.14 5.04 -74,548 2,302,440
2022-06-29 2022-06-27 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -14,220 472,093 -2.92 7.20 -102,384 3,399,070
2022-05-19 2022-05-17 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -13,913 486,313 -2.78 5.32 -73,962 2,585,240
2022-03-03 2022-03-01 4 ATRA Atara Biotherapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 339,419 339,419
2022-03-03 2022-03-01 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -8,828 500,226 -1.73 9.86 -87,009 4,930,227
2022-03-03 2022-03-01 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 180,565 509,054 54.97
2021-11-18 2021-11-16 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -8,402 328,489 -2.49 17.12 -143,816 5,622,713
2021-08-19 2021-08-17 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -8,223 336,891 -2.38 12.53 -103,051 4,221,918
2021-06-29 2021-06-25 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -14,194 345,114 -3.95 16.32 -231,660 5,632,606
2021-05-20 2021-05-18 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -8,313 359,308 -2.26 14.55 -120,954 5,227,931
2021-03-04 2021-03-02 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -4,887 367,621 -1.31 16.74 -81,808 6,153,976
2021-03-03 2021-03-01 4 ATRA Atara Biotherapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 176,886 176,886
2021-03-03 2021-03-01 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 117,187 372,508 45.90
2020-11-18 2020-11-17 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -4,716 255,321 -1.81 19.77 -93,254 5,048,717
2020-08-20 2020-08-18 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -4,807 260,037 -1.82 12.09 -58,117 3,143,847
2020-06-26 2020-06-25 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -12,135 264,844 -4.38 12.92 -156,784 3,421,784
2020-05-20 2020-05-18 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
S - Sale X -3,195 276,979 -1.14 11.22 -35,848 3,107,704
2020-03-03 2020-03-01 4 ATRA Atara Biotherapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 242,000 242,000
2020-03-03 2020-03-01 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 150,000 280,174 115.23
2020-01-28 2020-01-24 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
F - Taxes -9,900 130,174 -7.07 13.62 -134,838 1,772,970
2019-06-25 2019-06-24 4 ATRA Atara Biotherapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 225,000 225,000
2019-06-25 2019-06-24 4 ATRA Atara Biotherapeutics, Inc.
Common Stock
A - Award 140,074 140,074
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)